StockData
PTC Therapeutics, Inc. logo

PTC Therapeutics, Inc. (PTCT) stock

PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3029% above fair value
$60.23−0.13 (-0.22%)

Close on Nov 18, 2026Market cap $5.03BP/E –Yield –

PTC Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

PTC Therapeutics's free cash flow for the twelve months ending Sep 30, 2026 was $2.07M, down 99.7% year over year. For fiscal 2025 it was $702.34M. The highest annual figure on record is $702.34M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$702.34M–
FY2024Dec 31, 2024-$114.19M–
FY2023Dec 31, 2023-$186.86M–
FY2022Dec 31, 2022-$388.67M–
FY2021Dec 31, 2021-$279.55M–
FY2020Dec 31, 2020-$211.91M–
FY2019Dec 31, 2019-$112.40M–
FY2018Dec 31, 2018-$34.74M–
FY2017Dec 31, 2017-$13.16M–
FY2016Dec 31, 2016-$105.34M–
FY2015Dec 31, 2015-$127.06M–
FY2014Dec 31, 2014-$61.94M–
FY2013Dec 31, 2013-$47.77M–
FY2012Dec 31, 2012-$48.12M–
FY2011Dec 31, 2011-$20.93M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$27.97M–
Q2 FY2026Jun 30, 2026$126.92M–
Q1 FY2026Mar 31, 2026-$60.24M-106.9%
Q4 FY2025Dec 31, 2025-$36.65M–
Q3 FY2025Sep 30, 2025-$69.82M–
Q2 FY2025Jun 30, 2025-$59.58M–
Q1 FY2025Mar 31, 2025$868.38M+1319.5%
Q4 FY2024Dec 31, 2024-$33.77M–
Q3 FY2024Sep 30, 2024-$77.51M–
Q2 FY2024Jun 30, 2024-$64.08M–
Q1 FY2024Mar 31, 2024$61.17M–
Q4 FY2023Dec 31, 2023-$105.85M–
Q3 FY2023Sep 30, 2023-$20.88M–
Q2 FY2023Jun 30, 2023-$20.37M–
Q1 FY2023Mar 31, 2023-$39.76M–
Q4 FY2022Dec 31, 2022-$174.59M–
Q3 FY2022Sep 30, 2022-$43.43M–
Q2 FY2022Jun 30, 2022-$63.94M–
Q1 FY2022Mar 31, 2022-$106.72M–
Q4 FY2021Dec 31, 2021-$77.57M–
Q3 FY2021Sep 30, 2021-$57.03M-344.2%
Q2 FY2021Jun 30, 2021-$39.12M–
Q1 FY2021Mar 31, 2021-$105.83M–
Q4 FY2020Dec 31, 2020-$70.72M–
Q3 FY2020Sep 30, 2020$23.35M–
Q2 FY2020Jun 30, 2020-$76.97M–
Q1 FY2020Mar 31, 2020-$87.58M–
Q4 FY2019Dec 31, 2019-$14.86M–
Q3 FY2019Sep 30, 2019-$19.76M-1052.0%
Q2 FY2019Jun 30, 2019-$32.51M–
Q1 FY2019Mar 31, 2019-$45.27M–
Q4 FY2018Dec 31, 2018-$19.75M-202.6%
Q3 FY2018Sep 30, 2018$2.08M–
Q2 FY2018Jun 30, 2018-$705.00K-105.4%
Q1 FY2018Mar 31, 2018-$16.36M–
Q4 FY2017Dec 31, 2017$19.25M–
Q3 FY2017Sep 30, 2017-$16.25M–
Q2 FY2017Jun 30, 2017$12.97M–
Q1 FY2017Mar 31, 2017-$29.13M–
Q4 FY2016Dec 31, 2016-$14.56M–

More PTC Therapeutics figures

See a number that looks wrong?